A Descriptive 5‐Year Analysis of the Demographics and Therapies for Patients With Immune Thrombotic Thrombocytopenic Purpura in the USA: A Multicenter Study of 390 Disease Episodes From 2017 to 2021
Jacobs J, Adkins B, Booth G, Stanek C, Allen E, Grossman B, Stephens L, Crowe E, Daou L, Marques M, Siniard R, Wallace L, Yamada C, Duque M, Wu Y, Aljuboori O, Harrington T, Byrnes D, Eichbaum Q, Villalba C, Juskewitch J, Klapper E, Perez‐Alvarez I, Klein M, Aldarweesh F, Alkhateb R, Parsons M, Schlueter A, Tormey C, Wheeler A, Powers A, Webb C, Yates S, Bloch E, Raval J. A Descriptive 5‐Year Analysis of the Demographics and Therapies for Patients With Immune Thrombotic Thrombocytopenic Purpura in the USA: A Multicenter Study of 390 Disease Episodes From 2017 to 2021. Journal Of Clinical Apheresis 2025, 40: e70017. PMID: 40145682, PMCID: PMC11948952, DOI: 10.1002/jca.70017.Peer-Reviewed Original ResearchConceptsImmune thrombotic thrombocytopenic purpuraTherapeutic plasma exchangeThrombotic thrombocytopenic purpuraThrombocytopenic purpuraStandardization of treatment regimensMicroangiopathic hemolytic anemiaThirty-day mortalityPlasma exchangeADAMTS13 deficiencyThirty-dayMulticenter studyTreatment regimensHemolytic anemiaMicrovascular occlusionInitial episodesReplacement fluidCaplacizumabTherapeutic agentsPatientsDisease episodesPurpuraMortalityTherapyEpisodesTreatment practices
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply